308 related articles for article (PubMed ID: 28118167)
21. Comparative cognitive effects of levetiracetam and topiramate in intractable epilepsy.
Huang CW; Pai MC; Tsai JJ
Psychiatry Clin Neurosci; 2008 Oct; 62(5):548-53. PubMed ID: 18950374
[TBL] [Abstract][Full Text] [Related]
22. Are psychiatric adverse events of antiepileptic drugs a unique entity? A study on topiramate and levetiracetam.
Mula M; Trimble MR; Sander JW
Epilepsia; 2007 Dec; 48(12):2322-6. PubMed ID: 17711462
[TBL] [Abstract][Full Text] [Related]
23. Temozolomide treatment does not affect topiramate and oxcarbazepine plasma concentrations in chronically treated patients with brain tumor-related epilepsy.
Maschio M; Albani F; Jandolo B; Zarabla A; Contin M; Dinapoli L; Fabi A; Pace A; Baruzzi A
J Neurooncol; 2008 Nov; 90(2):217-21. PubMed ID: 18612799
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and tolerability of the new antiepileptic drugs, I: Treatment of new-onset epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society.
French JA; Kanner AM; Bautista J; Abou-Khalil B; Browne T; Harden CL; Theodore WH; Bazil C; Stern J; Schachter SC; Bergen D; Hirtz D; Montouris GD; Nespeca M; Gidal B; Marks WJ; Turk WR; Fischer JH; Bourgeois B; Wilner A; Faught RE; Sachdeo RC; Beydoun A; Glauser TA; ; ; ;
Epilepsia; 2004 May; 45(5):401-9. PubMed ID: 15101821
[TBL] [Abstract][Full Text] [Related]
25. Levetiracetam selectively potentiates the acute neurotoxic effects of topiramate and carbamazepine in the rotarod test in mice.
Luszczki JJ; Andres MM; Czuczwar P; Cioczek-Czuczwar A; Wojcik-Cwikla J; Ratnaraj N; Patsalos PN; Czuczwar SJ
Eur Neuropsychopharmacol; 2005 Dec; 15(6):609-16. PubMed ID: 15922567
[TBL] [Abstract][Full Text] [Related]
26. Comparison of the efficacy and tolerability of new antiepileptic drugs: what can we learn from long-term studies?
Zaccara G; Messori A; Cincotta M; Burchini G
Acta Neurol Scand; 2006 Sep; 114(3):157-68. PubMed ID: 16911343
[TBL] [Abstract][Full Text] [Related]
27. Effect of age and comedication on levetiracetam pharmacokinetics and tolerability.
Hirsch LJ; Arif H; Buchsbaum R; Weintraub D; Lee J; Chang JT; Resor SR; Bazil CW
Epilepsia; 2007 Jul; 48(7):1351-9. PubMed ID: 17573925
[TBL] [Abstract][Full Text] [Related]
28. Effects of treatment with clinically relevant valproate, carbamazepine, oxcarbazepine, topiramate, lamotrigine and levetiracetam on ovarian folliculogenesis in young rats.
Cansu A; Gurgen SG; Demirhan YN; Ozkan Kart P; Yildirim M; Alver A; Yeni Lmez E; Sönmez FM
Epilepsy Res; 2022 Aug; 184():106966. PubMed ID: 35763982
[TBL] [Abstract][Full Text] [Related]
29. Long-term effectiveness and tolerability of topiramate in children with epilepsy under the age of 2 years: 4-year follow-up.
Kim JM; Kwon S; Seo HE; Choe BH; Cho MH; Park SP
J Korean Med Sci; 2009 Dec; 24(6):1078-82. PubMed ID: 19949663
[TBL] [Abstract][Full Text] [Related]
30. Pharmacodynamic and pharmacokinetic interaction studies of loreclezole with felbamate, lamotrigine, topiramate, and oxcarbazepine in the mouse maximal electroshock seizure model.
Luszczki JJ; Ratnaraj N; Patsalos PN; Czuczwar SJ
Epilepsia; 2005 Mar; 46(3):344-55. PubMed ID: 15730531
[TBL] [Abstract][Full Text] [Related]
31. Lack of pharmacokinetic interaction of levetiracetam on carbamazepine, valproic acid, topiramate, and lamotrigine in children with epilepsy.
Otoul C; De Smedt H; Stockis A
Epilepsia; 2007 Nov; 48(11):2111-5. PubMed ID: 17651416
[TBL] [Abstract][Full Text] [Related]
32. Isobolographic characterization of interactions of levetiracetam with the various antiepileptic drugs in the mouse 6 Hz psychomotor seizure model.
Wojda E; Wlaz A; Patsalos PN; Luszczki JJ
Epilepsy Res; 2009 Oct; 86(2-3):163-74. PubMed ID: 19596559
[TBL] [Abstract][Full Text] [Related]
33. Long-term levetiracetam treatment of epilepsy patients: clinical audit.
Kuba R; Novotná I; Brázdil M; Kocvarová J; Tyrliková I; Mastík J; Rektor I
Epilepsy Res; 2006 Dec; 72(2-3):111-9. PubMed ID: 16930945
[TBL] [Abstract][Full Text] [Related]
34. Retention rate of levetiracetam in children with intractable epilepsy at 1 year.
Peake D; Mordekar S; Gosalakkal J; Mukhtyar B; Buch S; Crane J; Wheway R; Rittey C; Donnelly J; Whitehouse WP; Philip S
Seizure; 2007 Mar; 16(2):185-9. PubMed ID: 17258474
[TBL] [Abstract][Full Text] [Related]
35. A randomized, open-label, multicenter comparative trial of levetiracetam and topiramate as adjunctive treatment for patients with focal epilepsy in Korea.
Lee SK; Lee SA; Kim DW; Loesch C; Pelgrims B; Osakabe T; Lee B;
Epilepsy Behav; 2019 Aug; 97():67-74. PubMed ID: 31195326
[TBL] [Abstract][Full Text] [Related]
36. Novel anticonvulsant drugs.
Stefan H; Feuerstein TJ
Pharmacol Ther; 2007 Jan; 113(1):165-83. PubMed ID: 17030393
[TBL] [Abstract][Full Text] [Related]
37. Long-term assessment of oxcarbazepine in a naturalistic setting: a retrospective study.
Seneviratne U; D'Souza W; Cook M
Acta Neurol Scand; 2008 May; 117(5):367-9. PubMed ID: 18028241
[TBL] [Abstract][Full Text] [Related]
38. Topiramate monotherapy in the treatment of newly or recently diagnosed epilepsy.
Ben-Menachem E; Sander JW; Stefan H; Schwalen S; Schäuble B
Clin Ther; 2008 Jul; 30(7):1180-95. PubMed ID: 18691980
[TBL] [Abstract][Full Text] [Related]
39. Preclinical profile of combinations of some second-generation antiepileptic drugs: an isobolographic analysis.
Luszczki JJ; Czuczwar SJ
Epilepsia; 2004 Aug; 45(8):895-907. PubMed ID: 15270754
[TBL] [Abstract][Full Text] [Related]
40. Relationship between mono-hydroxy-carbazepine serum concentrations and adverse effects in patients on oxcarbazepine monotherapy.
Sattler A; Schaefer M; May TW
Seizure; 2015 Sep; 31():149-54. PubMed ID: 26362393
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
